The Current Issue
Explore the complete editorial contents, Table of Contents, and full-color digital compendium for Volume 14: The Cellular Reprogramming Frontier.
The Cellular Reprogramming Frontier
How controlled OSK Yamanaka factor pulses reverse tissue senescence without teratoma oncogenesis.
When Aging Becomes an Engineering Challenge
“For centuries, biological senescence was treated as an inevitable thermodynamic degradation of living matter. Yet the latest preclinical data from Basel, Cambridge, and Stanford proves cellular aging is largely epigenetic software degradation rather than irreversible hardware collapse.”
“In this quarterly issue, we investigate how transient partial reprogramming erased 4.2 years of vascular endothelial age, visit the autonomous acoustic droplet peptide foundry testing 10,000 AI macrocycles a week, and track the first regulatory clearances for in-vivo prime editing.”
Table of Contents • Volume 14
Rewriting the Epigenetic Clock: Partial Reprogramming
From Code to Crystal: The Autonomous Drug Foundry
Prime Editing 3.0: Erasing Monogenic CNS Mutations
The Industrial Microbe: Fermentation Replaces Polymers
The Q3 BioCapital Report: $14B Deployed in Degitizers
Light Over Silicon: Optogenetic Prosthetic Actuation
Issue Highlights & Full Stories
View All Published Dossiers →
LongevityRewriting the Epigenetic Clock: Can Partial Reprogramming Reverse Human Tissue Aging?
For decades, cellular aging was viewed as an irreversible thermodynamic decline. Today, epigenetic reprogramming is transforming senescence from an inevitable fate into an engineering challenge.
AI & DiscoveryFrom Code to Crystal: Inside the Fully Autonomous Generative Drug Foundry
Physical pipettes are giving way to acoustic liquid handlers driven by reinforcement learning agents, collapsing the lead discovery pipeline from 4 years to 14 days.
GenomicsPrime Editing 3.0: Erasing Monogenic Neurological Mutations In Vivo
Double-strand breaks and random indels have plagued clinical CRISPR. The latest generation of engineered pegRNA architectures eliminates off-target cleavage entirely.
Looking for previous quarterly editions?
Browse our past volume archives from 2025 to 2026, including special editions on generative protein design and synthetic organoids.